Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2011-09-07

FDA Approved: LATISSE — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

The FDA approved Allergan’s supplemental application for LATISSE (bimatoprost), expanding the product’s labeling for eyelash growth.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LATISSE (BIMATOPROST)

Snippet

SUPPL AP for LATISSE (BIMATOPROST)